Systemic Lupus Erythematosus, New England Journal of Medicine, vol.365, issue.22, pp.2110-2131, 2011. ,
DOI : 10.1056/NEJMra1100359
Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices, Best Practice & Research Clinical Rheumatology, vol.19, issue.5, pp.685-708, 2005. ,
DOI : 10.1016/j.berh.2005.03.010
Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation, Clinical Journal of the American Society of Nephrology, vol.5, issue.2, pp.341-58, 2010. ,
DOI : 10.2215/CJN.07111009
Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation, Am J Transplant, vol.7, pp.2496-503, 2007. ,
Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies, Clin Pharmacokinet, vol.47, pp.277-84, 2008. ,
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure, Transplantation Reviews, vol.25, issue.2, pp.47-57, 2011. ,
DOI : 10.1016/j.trre.2010.06.001
URL : https://hal.archives-ouvertes.fr/inserm-00926489
A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil, Clin Pharmacokinet, vol.44, issue.10, pp.837-884, 2005. ,
Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods, Ther Drug Monit, vol.27, issue.11, pp.354-61, 2005. ,
Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation, Clin Pharmacokinet, vol.48, pp.667-75, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00377174
The Measurement of Observer Agreement for Categorical Data, Biometrics, vol.33, issue.1 ,
DOI : 10.2307/2529310
The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set, Arthritis Rheum, vol.52, pp.2854-64, 2005. ,
Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil, Nephrology Dialysis Transplantation, vol.23, issue.11, pp.3514-3534, 2008. ,
DOI : 10.1093/ndt/gfn360
Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus, British Journal of Clinical Pharmacology, vol.49, issue.5, pp.727-767, 2012. ,
DOI : 10.1111/j.1365-2125.2011.04140.x
A Brief Introduction to Monte Carlo Simulation, Clinical Pharmacokinetics, vol.17, issue.1, pp.15-22, 2001. ,
DOI : 10.2165/00003088-200140010-00002
Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil, Arthritis Rheum, vol.62, pp.2047-54, 2010. ,
Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus, Semin Arthritis Rheum, vol.40, pp.307-320, 2011. ,
Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients, Clinical Pharmacokinetics, vol.18, issue.2, pp.13-58, 2007. ,
DOI : 10.2165/00003088-200746010-00002
UGT1A9 -275T>A/- 2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients, Clin Pharmacol Ther, vol.86, issue.22, pp.319-346, 2009. ,